
    
      Design: Randomized, placebo-controlled, double-blind trial. Setting: Outpatient clinics,
      White River Junction Veterans Affairs Medical Center.

      Patients: 57 men with crystal proven acute gout attack, at first medical contact, and within
      7 days onset.

      Intervention: Subjects were randomized to receive allopurinol 300mg daily or matching placebo
      for 10 days. All patients received indomethacin 50mg TID for 10 days, prophylactic dose
      colchicine 0.6mg BID for 90 days, and open-label allopurinol starting at day 11.

      Measurements: Primary outcomes were patient reported pain on visual analogue scale (VAS) for
      the primary joint, and self reported flares in any joint days 1-30. Secondary endpoints
      included urate, sedimentation rates, C-reactive protein levels.
    
  